Biovie is trading 6.3% down now at $1.92 after its Phase 2 ADDRESS-LC trial failed to achieve statistical significance across endpoints in the overall population.
- Significant findings were limited to prespecified subgroups and described as hypothesis-generating.
- The results weakened confidence in bezisterim’s Long COVID efficacy prospects; a conference call is scheduled for September 15.